1. Cytoskeleton
  2. Integrin
  3. BIO-1211

BIO-1211 is a highly selective and orally active α4β1 (VLA-4) inhibitor, with IC50 values of 4 nM and 2 μM for α4β1 and α4β7, respectively.

For research use only. We do not sell to patients.

Custom Peptide Synthesis

CAS No. : 187735-94-0

Size Price Stock Quantity
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO
ready for reconstitution
In-stock
Solution
10 mM * 1 mL in DMSO In-stock
Solid
1 mg In-stock
5 mg In-stock
10 mg In-stock
50 mg   Get quote  
100 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 3 publication(s) in Google Scholar

Top Publications Citing Use of Products
RT-PCR
WB
Cell Proliferation/Viability Assay
Cell Imaging/Staining

    BIO-1211 purchased from MedChemExpress. Usage Cited in: Leukemia. 2025 Aug 15.  [Abstract]

    Effect of cytokine signaling blockade on ALL cell survival in co-culture with stromal populations. ALL cells were co-cultured with early mesenchymal progenitors, adipogenic progenitors, or cultured alone. Effect of VCAM1 blockade on ALL cell viability in co-culture or monoculture. Effect of blocking integrin beta 1 (ITGB1) using a blocking antibody or the small peptidomimetic drug BIO-1211 (50 uM; 7 days), Mouse IgG1 kappa, Isotype Control (1 ug/mL; 7 days)on ALL cell viability in co-culture or monoculture.

    BIO-1211 purchased from MedChemExpress. Usage Cited in: Vascul Pharmacol. 2022 Dec:147:107113.  [Abstract]

    Different subtypes of integrin receptors lead to opposite trends in the effect of MK in regulating hepatic sinusoidal diastolic homeostasis. The effect of exogenous MK stimulation of Itgα4+ and Itgα6+ on NO, ET1, TXA2 expression and the reversal of NO, ET1, TXA2 expression by BIO1211 (4 nM in LSECs of Itgα4+; 100 μM in LSECs of Itgα6+) in LSECs.

    BIO-1211 purchased from MedChemExpress. Usage Cited in: Vascul Pharmacol. 2022 Dec:147:107113.  [Abstract]

    The effect of exogenous MK stimulation of Itgα4+ and Itgα6+ and BIO1211 (4 nM in LSECs of Itgα4+; 100 μM in LSECs of Itgα6+) in LSECs. WB detection of CAV-1 and Akt/eNOS signaling pathway expression, n = 3.

    BIO-1211 purchased from MedChemExpress. Usage Cited in: Vascul Pharmacol. 2022 Dec:147:107113.  [Abstract]

    The effect of exogenous MK stimulation of Itgα4+ and Itgα6+ and BIO1211 (4 nM in LSECs of Itgα4+; 100 μM in LSECs of Itgα6+) in LSECs. Immunofluorescence detection of CAV-1 expression in LSECs, Scale bar =100μm.

    BIO-1211 purchased from MedChemExpress. Usage Cited in: Vascul Pharmacol. 2022 Dec:147:107113.  [Abstract]

    MK induces hepatic sinusoidal contraction through integrin α6 promoting Src/Shc pathway. WB detection of the expression of Src/Shc signaling pathway in cells, n=3. BIO-1211 (4 nM in LSECs of Itgα4+; 100 μM in LSECs of Itgα6+).
    • Biological Activity

    • Purity & Documentation

    • References

    • Customer Review

    Description

    BIO-1211 is a highly selective and orally active α4β1 (VLA-4) inhibitor, with IC50 values of 4 nM and 2 μM for α4β1 and α4β7, respectively[1][2][3].

    IC50 & Target[3]

    α4β1

    4 nM (IC50)

    α4β7

    2 μM (IC50)

    Cellular Effect
    Cell Line Type Value Description References
    CHO IC50
    < 0.5 nM
    Compound: Bio-1211
    Inhibition of VLA-4 receptor expressed in CHO cells
    Inhibition of VLA-4 receptor expressed in CHO cells
    [PMID: 15582407]
    JY IC50
    2 μM
    Compound: 12
    Inhibition of integrin alpha4-beta7 adhesion to JY cells
    Inhibition of integrin alpha4-beta7 adhesion to JY cells
    [PMID: 10072689]
    JY IC50
    > 100 μM
    Compound: 12
    Inhibition of ICAM-1 transfected CHO cell adhesion to integrin alphaL-beta2 of human JY cells
    Inhibition of ICAM-1 transfected CHO cell adhesion to integrin alphaL-beta2 of human JY cells
    [PMID: 10072689]
    Jurkat IC50
    0.13 nM
    Compound: 2
    Inhibition of [125I]VCAM-Ig binding to Alpha-4 beta-1 (VLA-4) of Jurkat cells
    Inhibition of [125I]VCAM-Ig binding to Alpha-4 beta-1 (VLA-4) of Jurkat cells
    [PMID: 11844701]
    Jurkat IC50
    0.13 nM
    Compound: BIO-1211
    Antagonistic activity against VLA-4 integrin of human jurkat cells using [125I]VCAM-Ig as radioligand
    Antagonistic activity against VLA-4 integrin of human jurkat cells using [125I]VCAM-Ig as radioligand
    [PMID: 11591507]
    Jurkat IC50
    0.3 nM
    Compound: BIO-1211
    Inhibition of Integrin alpha-4-beta-1-mediated adhesion in human jurkat cells
    Inhibition of Integrin alpha-4-beta-1-mediated adhesion in human jurkat cells
    [PMID: 16767086]
    Jurkat IC50
    4 nM
    Compound: 12
    Inhibition of integrin alpha4-beta1 adhesion to Jurkat cells
    Inhibition of integrin alpha4-beta1 adhesion to Jurkat cells
    [PMID: 10072689]
    Jurkat IC50
    4.8 nM
    Compound: 1, BIO1211, MPUPA-LDVP-OH
    Displacement of [125I]-FN from human alpha4beta1 integrin expressed in human Jurkat cells by scintillation proximity assay
    Displacement of [125I]-FN from human alpha4beta1 integrin expressed in human Jurkat cells by scintillation proximity assay
    [PMID: 24412498]
    Jurkat IC50
    7.6 nM
    Compound: 1, BIO1211, MPUPA-LDVP-OH
    Inhibition of human alpha4beta1 integrin expressed in human Jurkat cells assessed as inhibition of cell adhesion to VCAM-1
    Inhibition of human alpha4beta1 integrin expressed in human Jurkat cells assessed as inhibition of cell adhesion to VCAM-1
    [PMID: 24412498]
    Jurkat IC50
    7.6 nM
    Compound: BIO1211
    Inhibition of human alpha4beta1 integrin expressed in human Jurkat cells assessed as inhibition of cell adhesion to VCAM-1
    Inhibition of human alpha4beta1 integrin expressed in human Jurkat cells assessed as inhibition of cell adhesion to VCAM-1
    [PMID: 26101577]
    K562 IC50
    > 100 μM
    Compound: 12
    Inhibition of integrin alpha1-beta1 adhesion using K562 cells expressing alpha-1
    Inhibition of integrin alpha1-beta1 adhesion using K562 cells expressing alpha-1
    [PMID: 10072689]
    K562 IC50
    > 100 μM
    Compound: 12
    Inhibition of integrin alpha5-beta1 adhesion to K562 cells
    Inhibition of integrin alpha5-beta1 adhesion to K562 cells
    [PMID: 10072689]
    K562 IC50
    > 100 μM
    Compound: 12
    Inhibition of integrin alpha6-beta1 adhesion using K562 cells expressing alpha-6
    Inhibition of integrin alpha6-beta1 adhesion using K562 cells expressing alpha-6
    [PMID: 10072689]
    RPMI-8866 IC50
    433 nM
    Compound: BIO-1211
    Inhibition of [125I]VCAM-Ig binding to alpha4-beta7 integrin of human RPMI-8866 cells
    Inhibition of [125I]VCAM-Ig binding to alpha4-beta7 integrin of human RPMI-8866 cells
    [PMID: 11591507]
    RPMI-8866 IC50
    862 nM
    Compound: BIO-1211
    Inhibition of [125I]MAdCAM-Ig binding to alpha4-beta7 integrin of human RPMI-8866 cells
    Inhibition of [125I]MAdCAM-Ig binding to alpha4-beta7 integrin of human RPMI-8866 cells
    [PMID: 11591507]
    In Vitro

    BIO-1211 almostly exhibits no activity for α1β1, α5β1, α6β1, αLβ2 and αIIbβ3[3].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    In Vivo

    BIO-1211 (5 and 10 mg/kg, orally, once every other day) results in reduced cytokines expression, leukocyte trafficking, and inhibition of inflammatory responses in EAE in a dose-independent manner. BIO-1211 exhibits a considerable depletion in the EAE clinical score, which correlated with decreased expression of TNF-α, IL-17, IFN-γ and pervade of CD11b+ and CD45+ cells into the cerebral cortex[2].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    Animal Model: Naive, C57BL/6 mice (male, 8 weeks old, 20-25 g weight)[2].
    Dosage: 5 and 10 mg/kg.
    Administration: Orally once every other day starting the day before immunization until day 21 post-immunization.
    Result: Could prevent the induction of EAE.
    Significantly delayed the onset of EAE and reduced the severity of clinical EAE compared to the vehicle group.
    Markedly reduced the expression of both CD11b and CD45 in comparison with the vehicle group.
    mRNA and soluble form of a subset of target inflammatory cytokines (IFNγ, IL-17, and TNF-α) was dramatically decreased.
    Molecular Weight

    708.80

    Formula

    C36H48N6O9

    CAS No.
    Appearance

    Solid

    Color

    White to off-white

    Shipping

    Room temperature in continental US; may vary elsewhere.

    Storage

    Sealed storage, away from moisture

    Powder -80°C 2 years
    -20°C 1 year

    *In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

    Solvent & Solubility
    In Vitro: 

    DMSO : 250 mg/mL (352.71 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

    Preparing
    Stock Solutions
    Concentration Solvent Mass 1 mg 5 mg 10 mg
    1 mM 1.4108 mL 7.0542 mL 14.1084 mL
    5 mM 0.2822 mL 1.4108 mL 2.8217 mL
    View the Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

    • Molarity Calculator

    • Dilution Calculator

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    Mass
    =
    Concentration
    ×
    Volume
    ×
    Molecular Weight *

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    Concentration (start)

    C1

    ×
    Volume (start)

    V1

    =
    Concentration (final)

    C2

    ×
    Volume (final)

    V2

    In Vivo:

    Select the appropriate dissolution method based on your experimental animal and administration route.

    For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
    To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
    The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

    • Protocol 1

      Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

      Solubility: ≥ 2.08 mg/mL (2.93 mM); Clear solution

      This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

      Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

      Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
    • Protocol 2

      Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in Saline)

      Solubility: ≥ 2.08 mg/mL (2.93 mM); Clear solution

      This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

      Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

      Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
    In Vivo Dissolution Calculator
    Please enter the basic information of animal experiments:

    Dosage

    mg/kg

    Animal weight
    (per animal)

    g

    Dosing volume
    (per animal)

    μL

    Number of animals

    Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
    Please enter your animal formula composition:
    %
    DMSO +
    +
    %
    Tween-80 +
    %
    Saline
    Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
    The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
    Calculation results:
    Working solution concentration: mg/mL
    Method for preparing stock solution: mg drug dissolved in μL  DMSO (Stock solution concentration: mg/mL).

    *In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

    The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
    Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.
     If the continuous dosing period exceeds half a month, please choose this protocol carefully.
    Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
    Purity & Documentation
    References

    Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

    Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
    DMSO 1 mM 1.4108 mL 7.0542 mL 14.1084 mL 35.2709 mL
    5 mM 0.2822 mL 1.4108 mL 2.8217 mL 7.0542 mL
    10 mM 0.1411 mL 0.7054 mL 1.4108 mL 3.5271 mL
    15 mM 0.0941 mL 0.4703 mL 0.9406 mL 2.3514 mL
    20 mM 0.0705 mL 0.3527 mL 0.7054 mL 1.7635 mL
    25 mM 0.0564 mL 0.2822 mL 0.5643 mL 1.4108 mL
    30 mM 0.0470 mL 0.2351 mL 0.4703 mL 1.1757 mL
    40 mM 0.0353 mL 0.1764 mL 0.3527 mL 0.8818 mL
    50 mM 0.0282 mL 0.1411 mL 0.2822 mL 0.7054 mL
    60 mM 0.0235 mL 0.1176 mL 0.2351 mL 0.5878 mL
    80 mM 0.0176 mL 0.0882 mL 0.1764 mL 0.4409 mL
    100 mM 0.0141 mL 0.0705 mL 0.1411 mL 0.3527 mL
    • No file chosen (Maximum size is: 1024 Kb)
    • If you have published this work, please enter the PubMed ID.
    • Your name will appear on the site.
    Help & FAQs
    • Do most proteins show cross-species activity?

      Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

    Your Recently Viewed Products:

    Inquiry Online

    Your information is safe with us. * Required Fields.

    Product Name

     

    Requested Quantity *

    Applicant Name *

     

    Salutation

    Email Address *

     

    Phone Number *

    Department

     

    Organization Name *

    City

    State

    Country or Region *

         

    Remarks

    Bulk Inquiry

    Inquiry Information

    Product Name:
    BIO-1211
    Cat. No.:
    HY-14126
    Quantity:
    MCE Japan Authorized Agent: